Valdecoxib

This page contains recent news articles, when available, and an overview of Valdecoxib but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Valdecoxib (when available)

Pharmacology and use:
Valdecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is classified as a nonsteroidal anti-inflammatory drug (NSAID). Valdecoxib is used for its anti-inflammatory, analgesic, and antipyretic activities in the management of osteoarthritis (OA) and for the treatment of dysmenorrhea or acute pain. Unlike celecoxib, Valdecoxib lacks a sulfonamide chain and does not require CYP450 enzymes for metabolism. For the treatment of osteoarthritis and dysmenorrhoea

Mechanism Of Action:
Both COX-1 and COX-2 catalyze the conversion of arachidonic acid to prostaglandin (PG) H2, the precursor of PGs and thromboxane. Valdecoxib selectively inhibits the cyclooxygenase-2 (COX-2) enzyme, important for the mediation of inflammation and pain. Unlike non-selective NSAIDs, Valdecoxib does not inhibit platelet aggregation.

News Articles on Valdecoxib

The Pharmaceutical Industrial Complex: A Deadly Fairy Tale  -  ‎Oct 23, 2009‎
A separate FOI concerning a similar drug, Valdecoxib, had pages and paragraphs deleted because sections of the document were marked as “trade secrets. ... Auburn Journal

Stevens-johnson syndrome  -  ‎Oct 23, 2009‎
...vcitane roznych liekov(wikipedia uvadza napr(allopurinol, diclofenac, etravirine, fluconazole,[2] valdecoxib, sitagliptin, oseltamivir, penicillins, ... Zdravie.sk

Ex-Sales Manager Gets Probation, $75000 Fine for Off-Label Promos  -  ‎Jun 19, 2009‎
According to the release, the Branchburg, NJ, woman orchestrated efforts to promote the pain drug Bextra (valdecoxib) for off-label uses and at unapproved Thompson.com

Sales Exec’s Guilty Plea Prolongs Bextra Fallout  -  ‎Mar 31, 2009‎
Apparently, the Bextra (valdecoxib) nightmare is lingering a bit longer for Pfizer. More than four years after the initial lawsuits against the drug were Pharmaceutical Technology Magazine

US Attorney Notifies Merck of Vioxx Investigation  -  ‎Apr 6, 2009‎
...if Pfizer’s recent $2.3 billion settlement with the US Attorney of Massachusetts for promotion of Cox-2 inhibitor Bextra (valdecoxib) is any indicator. FDA news (subscription)

Stellungnahme deutscher Schmerzforscher zum Fall "Scott Reuben"  -  ‎Mar 30, 2009‎
Zum Einsatz kam in ca. einem Viertel dieser Studien der Wirkstoff Celecoxib, in jeweils einer Studie Rofecoxib, Valdecoxib oder Parecoxib und in drei der Informationsdienst Wissenschaft (Pressemitteilung)

US researcher fabricated pain studies  -  ‎Mar 12, 2009‎
...such as Merck & Co’s Vioxx (rofecoxib) and Pfizer’s Celebrex (celecoxib), and Bextra (valdecoxib). He had argued that using these drugs in combination Pharma Times

Multi-modal, Pre-emptive Analgesia Decreases the Length of ...  -  ‎Mar 4, 2009‎
...a COX-2 inhibitor celecoxib (200 mg preop and 200 every 12 hours during hospitalization) or valdecoxib (10 mg per day preop and during hospitalization). Ortho SuperSite

Pfizer to Pay Billions for Alleged Off-Label Promotions  -  Jan 29, 2009
...attorney for the District of Massachusetts, the Bextra (valdecoxib) allegations and “other open investigations,�? the company says in its year-end statement. FDA news (subscription),

Pfizer net income falls 90% and confirms more job cuts  -  Jan 27, 2009
Net profit came in at $266 million due principally to a $2.3-billion charge taken to settle lawsuits concerning the pain drugs Bextra (valdecoxib). Pharma Times,

Warnings about side effects of NSAIDs  -  Jan 21, 2009
COX-2 inhibitors called valdecoxib (brand name Bextra) and rofecoxib (Vioxx) have been taken off the market because of their side effects. guardian.co.uk,

Pfizer mit deutlichem Gewinnrückgang im vierten Quartal 2008  -  Jan 27, 2009
Belastungen gab es unter anderem wegen des Konzernumbaus und der Beilegung von Rechtsstreitigkeiten zum ehemaligen Pfizer-Präparat Bextra® (Valdecoxib). Ärzte Zeitung,

Lotta senza quartiere ai farmacikiller  -  Nov 10, 2008
Oggi è lunga la lista dei farmaci a rischio, dagli analgesici Cox2 (valdecoxib, lumiracoxib) sospettati di avere effetti epatici, agli antinfiammatori La Repubblica,

Pfizer to settle Celebrex and Bextra suits for $894 million  -  21 Oct 2008
...has agreed in principle to pay $894 million to resolve most legal claims surrounding its COX-2 inhibitors, Celebrex (celecoxib) and Bextra (valdecoxib). Scrip World Pharmaceutical News (subscription),

New rofecoxib data will help inform treatment decisions with other ...  -  Oct 13, 2008
...risk associated with parecoxib and valdecoxib when these drugs were given immediately after coronary artery bypass grafting," say Baigent and Patrono. TheHeart.Org,

Common OTC Drug Could Pose Serious Risk For Some  -  16 Sep 2008
Not long after, valdecoxib, marketed as Bextra, was removed for the same reason. Since then, anxieties surrounding the cardiovascular safety of nonselective eMaxHealth.com,

Ibuprofen Use Increases Cardiovascular Risk but Not for All Older ...  -  Sep 5, 2008
Because of the concern created by the high-profile cardiovascular risks of rofecoxib and valdecoxib, the researchers decided to evaluate whether the risks MedPage Today,

Vioxx, Bextra linked to increased stroke risk: study  -  Aug 7, 2008
..."This study suggests that rofecoxib and valdecoxib were associated with higher stoke risk than other NSAIDs," Roumie said in the interview. Reuters India,

Study Confirms Vioxx and Bextra Dangers  -  Aug 8, 2008
...“This study suggests that rofecoxib (Vioxx) and valdecoxib (Bextra) were associated with higher stoke risk than other NSAIDs,�? Roumie said in the interview. Newsinferno.com,

Post-Withdrawl Study Confirms Vioxx, Bextra Link To Stroke Risk  -  Aug 7, 2008
Now a new study is adding to the evidence that Vioxx (rofecoxib) and withdrawn drug, Bextra (valdecoxib), both so-called “Cox-2�? inhibitors, should never InjuryBoard.com,

N-Terminal Pro-B-Type Natriuretic Peptide Concentrations Predict ...  -  Aug 9, 2008
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352: 1081- 91. 6. Bombardier C, Laine L, Reicin A, RedOrbit,

IDEA AG Gives an Update on the Development of Diractin, the ...  -  Jul 29, 2008
C0. announced the world-wide withdrawal of Vioxx® (rofecoxib) and in 2005, Pfizer Inc. was requested by the FDA to withdraw Bextra® (valdecoxib). PharmaLive.com (press release),

New Studies Target Lung Cancer Prevention, Imaging, and Treatment  -  Jul 15, 2008
...(Photo credit: Creative Living Art Enterprises, LLC/www.sciencesource.com) COX-2 inhibitors such as celecoxib, valdecoxib, and rofecoxib have made headlines Journal of American Medical Association (subscription),

Asocian a Vioxx y Bextra con mayor riesgo de accidente cerebral  -  Aug 8, 2008
..."Esto sugiere que rofecoxib y valdecoxib estaban asociados con un mayor riesgo de ACV que el resto de los AINE", dijo Roumie. Buena Salud

Public forum on "Health Care Financing"  -  Jun 8, 2008
In 2004, Merck announced the withdrawal of refecoxib (Vioxx) as it increases cardiovascular risk; this was followed by the withdrawal of valdecoxib (Bextra) Aliran Monthly,

Peer Review in the Balance  -  May 21, 2008
...valdecoxib (Bextra) and celecoxib (Celebrex) — 11 specific articles that we had published and any others that we had rejected for publication. New England Journal of Medicine (subscription),

The Deregulatory Effects of Preempting Tort Litigation  -  May 20, 2008
...approved cyclooxygenase 2 selective nonsteroidal anti-inflammatory drugs (refecoxib, valdecoxib) and type 2 diabetes medications (rosiglitazone). Journal of American Medical Association (subscription),

Breaking the faith  -  May 13, 2008
In relation to the ban on Vioxx, the Centre issued an order banning another Cox-2 drug, Valdecoxib. Nevertheless, this too is being stocked and distributed Express Pharma,

Problematic Evaluation of Drug Safety  -  Mar 27, 2008
Merck) and valdecoxib (Bextra, Pfizer), the delayed recognition of suicidality in children and young adults taking selective serotonin-reuptake Enews 2.0,

JAMA Editor-in-Chief welcomes ruling on Pfizer lawsuit  -  Mar 25, 2008
...journals concerning studies published on the pain relief medications called COX-2 inhibitors – (cyclooxygenase 2 inhibitors) celecoxib and valdecoxib. Hindu,

Court rejects Pfizer’s plea to take a peek at peer reviews  -  Mar 25, 2008
...with patients claiming to have suffered certain cardiovascular events after taking the now withdrawn Bextra (valdecoxib) and Celebrex (celecoxib), and, Pharma Times (subscription),

Court Protects Peer Review  -  Mar 25, 2008
...it hoped to use in its defense against more than 3000 lawsuits pertaining to how celecoxib and valdecoxib were advertised and marketed in the US. Medscape (subscription)

Medicinal Effects Questioned  -  Mar 10, 2008
This was the case with valdecoxib, a COX 2 inhibitor that failed to gain FDA approval to treat acute pain in 2001. As a result, some of the trial PsychCentral.com,

Brand Names/Synonyms:
Valdecoxib is also known by the following brand names and/or synonyms:
Bextra; Valdecoxib; Valdecoxib [Usan]

Drug Category:
Valdecoxib is categorized under the following by the FDA: Anti-inflammatory Agents; Nonsteroidal Antiinflammatory Agents (NSAIDs); ATC:M01AH03

Dosage Forms:
TABLET

Absorption:
Not Available

Interactions:
[an error occurred while processing this directive]

Chemical IUPAC Name:
4-(5-methyl-3-phenyl-oxazol-4-yl)benzenesulfonamide

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.